Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

GOSS
Gossamer Bio, Inc. Common Stock
stock NASDAQ

At Close
Jul 15, 2026 3:59:50 PM EDT
0.1700USD+20.200%(+0.0283)24,628,479
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Jul 15, 2026 9:27:30 AM EDT
0.1327USD-5.282%(-0.0074)48,248
After-hours
Jul 15, 2026 4:54:30 PM EDT
0.1635USD-2.910%(-0.0049)755,653
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Nov 9, 2021
11:24AM EST  SVB Leerink Maintains Outperform on Gossamer Bio, Raises Price Target to $16   Benzinga
11:02AM EST  Gossamer Bio Q3 EPS $(0.80) Misses $(0.78) Estimate   Benzinga
Nov 8, 2021
04:01PM EST  Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update   Business Wire
05:06AM EST  Earnings Scheduled For November 8, 2021   Benzinga
Nov 2, 2021
04:01PM EDT  Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021   Business Wire
Oct 11, 2021
08:39AM EDT  Gossamer Bio Announces Addition Of 2 CNS-Penetrant BTK Inhibitors To Product Candidate Pipeline: GB5121 & GB7208   Benzinga
Oct 7, 2021
04:01PM EDT  Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021   Business Wire
Sep 28, 2021
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
Sep 27, 2021
10:47AM EDT  Shares of Gossamer Bio, Inc. (GOSS) are gaining over 15% on Monday morning despite no stock-specific news to drive the shares.   RTTNews
Sep 21, 2021
08:57AM EDT  Biopharmaceutical company Gossamer Bio, Inc. (GOSS) announced Tuesday that Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer. Giraudo joined Gossamer in May 2018 as its Chief Financial Officer.   RTTNews
08:36AM EDT  Gossamer Bio Announces Appointment Of Bryan Giraudo As COO, In Addition To CFO Role   RTTNews
08:32AM EDT  Gossamer Bio Announces Appointment Of Bryan Giraudo As Chief Operating Officer   Benzinga
08:31AM EDT  Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role   Business Wire
Aug 10, 2021
04:48AM EDT  SVB Leerink Maintains Outperform on Gossamer Bio, Lowers Price Target to $15   Benzinga
Aug 9, 2021
04:05PM EDT  Gossamer Bio Q2 EPS $(0.80) Misses $(0.76) Estimate   Benzinga
04:01PM EDT  Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update   Business Wire
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 2, 2021
04:01PM EDT  Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021   Business Wire
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 7, 2021
07:04AM EDT  Gossamer Bio Announces GB004 Clinical Trial Data Presentations At 2021 Virtual Congress Of The European Crohn's And Colitis Organisation Jul. 8   Benzinga
07:01AM EDT  Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis Organisation   Business Wire
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 21, 2021
04:10PM EDT  Gossamer Bio Promotes Richard Aranda To Chief Medical Officer   RTTNews
04:02PM EDT  Gossamer Bio Names Richard Aranda As Chief Medical Officer   Benzinga
04:01PM EDT  Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer   Business Wire
Jun 14, 2021
04:01PM EDT  Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors   Business Wire
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 6, 2021
08:37AM EDT  Gossamer Bio Q1 EPS $(0.78) Up From $(0.87) YoY   Benzinga
07:31AM EDT  Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update   Business Wire
Mar 24, 2021
06:40AM EDT  HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Raises Price Target to $25   Benzinga
Feb 25, 2021
07:58AM EST  Gossamer Bio Q4 EPS $(0.88) Misses $(0.79) Estimate   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 4, 2021
07:05AM EST  Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021   Business Wire
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
08:31AM EST  Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 14, 2020: MRNA, LEN, WISH, RMG, GOSS   Benzinga
Dec 13, 2020
04:27PM EST  The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics   Benzinga
Dec 11, 2020
05:00PM EST  Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group.   GlobeNewswire Inc
Nov 16, 2020
07:17AM EST  Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer   Benzinga
07:16AM EST  Gossamer Bio Appoints Faheem Hasnain As CEO   RTTNews
07:01AM EST  Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer   Business Wire
Nov 10, 2020
04:03PM EST  Gossamer Bio Q3 EPS $(0.80) Beats $(0.85) Estimate   Benzinga
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
08:00AM EST  Aerpio Reports Third Quarter 2020 Financial Results and Provides   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 6, 2020
07:12AM EST  Gossamer Bio Announces GB1275 Data Presentations At Upcoming 2020 Society For Immunotherapy Of Cancer Annual Meeting Nov. 9-14   Benzinga
Oct 19, 2020
06:12AM EDT  HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $15   Benzinga
Oct 18, 2020
05:10PM EDT  Last Week's Notable Insider Buys: Carnival, Citigroup And More   Benzinga
Oct 14, 2020
09:20AM EDT  Cantor Fitzgerald Maintains Overweight on Gossamer Bio, Lowers Price Target to $20   Benzinga
Oct 13, 2020
02:38PM EDT  Mid-Afternoon Market Update: Dow Falls 200 Points; Gossamer Bio Shares Plummet   Benzinga
12:18PM EDT  Mid-Day Market Update: Gold Down 2%; Medigus Shares Spike Higher   Benzinga
11:19AM EDT  SVB Leerink Maintains Outperform on Gossamer Bio, Lowers Price Target to $29   Benzinga
10:37AM EDT  Shares of Gossamer Bio, Inc. (GOSS) are down more than 33% Tuesday morning after the company said the phase II b study of its drug candidate in patients with moderate-to-severe eosinophilic asthma did not meet primary end point and the phase II a study in patients with chronic rhinosinusitis did not meet primary or secondary endpoints.   RTTNews
10:11AM EDT  Mid-Morning Market Update: Markets Down; JPMorgan Profit Beats Estimates   Benzinga
08:39AM EDT  Shares of Gossamer Bio Inc. (GOSS) dropped more than 31 percent after the company said that two studies in GB001, phase 2b LEDA trial in moderate-to-severe eosinophilic asthma and Phase 2 TITAN trial in chronic rhinosinusitis, did not meet the primary endpoints. The company will discontinue development of GB001 in chronic rhinosinusitis.   RTTNews
07:12AM EDT  Gossamer Bio Says LEDA Study Did Not Achieve Statistical Significance On Primary Endpoint   RTTNews
07:10AM EDT  Gossamer Bio Announces Primary Endpoint Was Not Met In Phase 2 LEDA Trials Of Oral GB001 In Asthma And Chronic Rhinosinusitis; Shares Currently Halted   Benzinga
07:04AM EDT  Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis   Business Wire
Oct 12, 2020
08:13AM EDT  Gossamer Bio Announces Multiple Updates For Its GB004 Program   RTTNews
08:11AM EDT  Gossamer Bio To Present GB004 Phase 1b Clinical Data At United European Gastroenterology Virtual Week 2020   Benzinga
08:07AM EDT  Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates   Business Wire
Sep 15, 2020
08:32AM EDT  Aerpio Announces Enrollment Completed In The 28-Day Phase 2 Razuprotafib Glaucoma Trial   Benzinga
Sep 7, 2020
11:00AM EDT  Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020   Business Wire
Sep 1, 2020
04:31PM EDT  Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the   PR Newswire
Aug 11, 2020
04:03PM EDT  Gossamer Bio Q2 EPS $(1.00) Down From $(0.74) YoY   Benzinga
Aug 10, 2020
08:00AM EDT  Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial   GlobeNewswire Inc
Jul 14, 2020
08:19AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:47AM EDT  Cantor Fitzgerald Reiterates Overweight on Gossamer Bio, Raises Price Target to $33   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC